Phase I/II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Relapsed/Refractory CLL


Phase I/II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Relapsed/Refractory CLL
Slides from a presentation at ASH 2015 and a publication in The New England Journal of Medicine and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Byrd JC et al. The Bruton tyrosine kinase (Btk) inhibitor ACP-196: Marked activity in relapsed/refractory CLL with a favorable safety profile. Proc ASH 2015;Abstract 831.

Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):323-32. Abstract

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.